U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526350) titled 'MTS109 in Patients With Refractory Autoimmune Diseases' on April 06.
Brief Summary: This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
Study Start Date: March 24
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathies
Systemic Sclerosis (SSc)
ANCA-Associated Vasculitis (AAV)
Sjogren's Syndrome (SS)
Intervention:
DRUG: MTS109
Three subcutaneous injections will be administered on Days 1, 4, and 7. A low-dose priming approach will ...